Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
Date:5/8/2008

NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted under the direction of Ellen K. Ritchie, M.D. at The Weill-Cornell Medical College in New York City. Co- investigators for the study are Eric Feldman, M.D. and Gail Roboz, M.D.

The objectives of the trial are: (i) to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given in combination with cytarabine to AML and high-risk MDS patients over the age of 60, and (ii) to evaluate this combination further for safety and efficacy in a larger cohort of patients. Cloretazine(R) (VNP40101M) will be given as a 30 - 60 minute infusion on day 1 approximately 3-4 hours after the start of the cytarabine infusion. Cytarabine will be administered as a continuous infusion of 100 mg/m2/day for 7 days. In the Phase I portion of the study, dose escalation will be done in cohorts of at least 3 patients and the maximum tolerated dose (MTD) identified in the Phase I segment will be used in the Phase II segment of the study.

Ann Cahill, Vice President, Clinical Development, commented, "It is important for us to continue to study Cloretazine(R) (VNP40101M) in combination with different doses and schedules of cytarabine, the most widely used drug in the treatment of AML. In addition, we want to evaluate Cloretazine(R) (VNP40101M) in a broader group of elderly patients than are currently being studied in our pivotal tri
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
8. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
9. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
... , RYE, N.Y. , July 28 Curemark, ... on the treatment of neurological diseases, announced that Saint Peter,s University Hospital ... Phase III clinical trials for CM-AT , Curemark,s autism treatment.   ... Saint Peter,s is affiliated ...
... SEATTLE , July 28 HemaQuest Pharmaceuticals, ... for sickle cell disease, beta thalassemia and EBV-related cancers, ... to its Series B financing by new investor, ... B financing to $16M . The financing is ...
Cached Medicine Technology:Curemark Opens Autism Trials at New Jersey Site 2Curemark Opens Autism Trials at New Jersey Site 3HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed incident ... incident cases in 2013 to 11,568 diagnosed incident cases ... 4.35%, during the forecast period. In 2023, the US ... of aGVHD in the 6MM, with 4,989 diagnosed incident ... diagnosed incident cases of aGVHD, with 704 diagnosed incident ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
(Date:7/13/2014)... 13, 2014 Hope Palliative & Hospice Care ... support group at the Tamarack Senior Living Community in Palatine, ... 10:30 A.M. on the 3rd Wednesdays of every month. ... the Tamarack Community located at 55 S. Greeley St. Palatine, ... and there is no cost for the group. , ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers ... added a new selection of beautiful evening dresses ... a promotion for these evening gowns. Now, everybody can ... providing thousands of graceful gowns in its online store. ... France, Italy and many other countries. They are highly ...
(Date:7/12/2014)... July 12, 2014 The Chicken ... the past five years, buoyed by stable demand for ... management system. “Eggs are a relatively affordable staple for ... egg consumption generally grows in line with the size ... McKitterick. Furthermore, demand for new specialty egg products with ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... Feb. 26 Endo Pharmaceuticals (Nasdaq: ENDP ... to the company,s board of directors. Mr. Montague, ... of Mark IV Industries, retired in July last year. ... highly-engineered systems and components for the transportation, industrial and ...
... after sessions, study finds , , THURSDAY, Feb. 26 (HealthDay ... breast cancer patients, contends a new U.S. study. , ... many women with breast cancer experience, the opportunity to ... of breast cancer is a significant benefit," lead researcher ...
... Laboratories,the newly expanded dermatology division of Valeant Pharmaceuticals,International ... data presentations on Acanya,Gel at the 67th Annual ... place March 6 - 10, 2009, at the ... efficacy and safety of once daily Acanya Gel,(clindamycin ...
... Feb. 26 If you,re looking for an example ... Program, consider Wells Fargo Bank, which has received $25 ... bank has inexplicably withheld tens of thousands of dollars ... Southern California behavioral healthcare treatment center have used to ...
... The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com ... the fourth quarter ended December 31, 2008, compared to $10.7 million ... December 31, 2008, net sales were $20.5 million compared to $28.2 ... , The decrease in net sales for the fourth quarter ...
... All Levels of SocietyWASHINGTON, Feb. 26 A ... percent of colon cancer cases and 38 percent ... preventable through diet, physical activity and weight management. ... reduce the global number of cancer cases.The overall ...
Cached Medicine News:Health News:Endo Pharmaceuticals Appoints William Montague to Board of Directors 2Health News:Endo Pharmaceuticals Appoints William Montague to Board of Directors 3Health News:Yoga May Bring Calm to Breast Cancer Treatment 2Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 2Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 3Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 4Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 5Health News:According to A Better Tomorrow Wells Fargo's Credit Card Processing Division is Withholding Tens of Thousands of Dollars Owed to a Southern California-Based Behavioral Healthcare Treatment Center 2Health News:According to A Better Tomorrow Wells Fargo's Credit Card Processing Division is Withholding Tens of Thousands of Dollars Owed to a Southern California-Based Behavioral Healthcare Treatment Center 3Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 2Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 3Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 4Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 5Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 6Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 7Health News:Report: Many Cancers Could Be Prevented in US 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: